KRAS and lung cancer: Notably, PDX tumors derived from sample LF09—a lepidic ADC subtype and, therefore, linked to the non-aggressive lung cancer subtype—carried a KRAS oncogenic mutation and preserved the expression of Ki67 through the different passages, thus featuring enhanced aggressiveness (Supplementary Figure S5F).